Evidence map›Paper›PMID 39838682›Full record

ArticleCurrent medicinal chemistry2025

Delineating the Potential Therapeutic Effects of Lobaric Acid as a Novel Strategy in the Treatment of Melanoma.

Huda Abdirizak Jama, Mine Ensoy, Açelya Yılmazer, Demet Cansaran-Duman

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huda Abdirizak JamaBiotechnology Institute, Ankara University, Keçiören, TR-06135, Ankara, Turkey.
Mine EnsoyBiotechnology Institute, Ankara University, Keçiören, TR-06135, Ankara, Turkey.
Açelya YılmazerStem Cell Institute, Ankara University, Ankara, Turkey.
Demet Cansaran-DumanBiotechnology Institute, Ankara University, Keçiören, TR-06135, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMelanoma is one of the most dangerous and common types of cancer in humans. In order to minimize the toxicity and side effects of melanoma treatment, it is important to identify drug candidates that have strong anti-cancer activity and fewer side effects. Lobaric acid is a small molecule that has been found to have significant anti-cancer effects on various types of cancer cells.

methodsThe study aimed to investigate the effects of lobaric acid on human melanoma cell lines (A-375, MDA-MB-435, G-361, and WM-115) and normal human epidermal melanocyte cells. The study also examined the regulation of cell cycle and apoptosis, as well as the gene expression level of apoptosis-related genes and regulatory proteins to induce apoptosis in melanoma cells.

resultsThe study suggests that lobaric acid may have an effect on the proliferation of A-375 melanoma cells, with results indicating a dose- and time-dependent manner. Additionally, the study found that the expression levels of 70 target genes out of 88 apoptosis- related genes in the primary apoptosis library panel were obtained. Out of these, 54 genes showed an increase in expression levels, while 16 genes showed a decrease. Moreover, it has been determined that the levels of apoptosis-related proteins, such as

conclusionThe findings of this study provided a strong basis for the use of lobaric acid as a potential therapeutic agent in the treatment of melanoma.

Indexed as

Antineoplastic AgentsMelanomaApoptosisCell CycleCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansAntineoplastic Agentsapoptosiskoratinocytelobaric acidMelanomaneoplastic cancer.small molecule

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.